Bridging the Gap: JDRF’s Drive for Diabetes Technology Equity

For millions living with type 1 diabetes (T1D), advanced technologies like continuous glucose monitors (CGMs) and insulin pumps are not just conveniences—they are lifelines. These tools dramatically reduce the risk of severe hypoglycemia, improve time-in-range, and enhance quality of life. Yet, for individuals in low-income communities, access to these innovations remains profoundly unequal. JDRF, the world’s leading nonprofit organization dedicated to T1D research and advocacy, has recognized this disparity and is actively working to dismantle the barriers that keep advanced diabetes technology out of reach for underserved populations.

JDRF’s mission has expanded beyond funding cure-focused research to include a robust portfolio of initiatives aimed at health equity. These programs target the financial, educational, and systemic obstacles that disproportionately affect low-income individuals, ensuring that the benefits of cutting-edge technology are not reserved for the wealthy. This article explores the scope of that challenge, details JDRF’s key initiatives, and examines the measurable impact these efforts are having on communities across the United States and beyond.

The Landscape of Diabetes Technology Access

Understanding the Disparity

Advanced diabetes technologies—CGMs, insulin pumps, automated insulin delivery (AID) systems, and smart insulin pens—have been shown to improve glycemic control and reduce diabetes-related complications. According to the Centers for Disease Control and Prevention, individuals with T1D who use CGMs experience significantly fewer hospitalizations for diabetic ketoacidosis (DKA) and severe hypoglycemia. However, adoption rates among low-income populations are staggeringly low. A 2023 study published in Diabetes Care found that fewer than 25% of Medicaid beneficiaries with T1D used a CGM, compared to over 60% of those with private insurance.

The reasons are multifaceted. High out-of-pocket costs, lack of insurance coverage, limited access to endocrinologists, and a shortage of diabetes education in underserved communities all contribute to the gap. For families living paycheck to paycheck, the upfront cost of a CGM starter kit or the recurring expense of sensor supplies can be prohibitive. Even when insurance covers the device, prior authorization requirements and high deductibles can delay or block access entirely.

The Ripple Effect of Inequity

When advanced technologies are out of reach, health outcomes suffer. Low-income individuals with T1D are more likely to experience poor glycemic control, higher rates of DKA, and increased mortality. The American Diabetes Association reports that people with diabetes living in poverty are three times more likely to have diabetes-related hospitalizations. This not only harms patients but also strains the healthcare system—emergency visits for T1D complications cost billions annually. Addressing access is therefore both a moral imperative and a financial necessity.

JDRF has positioned itself at the center of this challenge. Through targeted programs, policy advocacy, and strategic partnerships, the organization is working to level the playing field, one device at a time.

JDRF’s Key Initiatives to Enhance Access

Financial Assistance Programs

JDRF recognizes that cost is the single most significant barrier to technology adoption. The organization has launched several grant and subsidy programs designed to directly reduce the financial burden on low-income individuals and families. These include:

  • Technology Assistance Grants: JDRF provides one-time grants of up to $2,000 to help cover the cost of CGM sensors, insulin pump supplies, and related consumables for eligible applicants. The program prioritizes individuals with household incomes at or below 200% of the federal poverty level.
  • Co-pay Assistance Funds: For those with insurance that requires high co-pays or deductibles, JDRF has established a co-pay relief fund that can offset out-of-pocket expenses by up to 80%. This program has helped hundreds of families maintain consistent use of their devices without facing financial hardship.
  • Device Donation and Recycling Programs: In partnership with device manufacturers, JDRF facilitates the donation of refurbished insulin pumps and CGMs to low-income clinics and patients. The JDRF Device Exchange program allows individuals to donate gently used devices, which are then cleaned, certified, and distributed to those in need.

These financial interventions have led to measurable increases in device adoption. Data from JDRF’s grant recipients show that within six months of receiving assistance, over 70% of participants improved their average blood glucose levels by at least 15 percentage points in time-in-range.

Educational Outreach and Community Empowerment

Even when devices are affordable, lack of knowledge about how to use them effectively can undermine their benefits. JDRF has invested heavily in culturally tailored diabetes education programs aimed at low-income and diverse communities.

Community Health Worker (CHW) Training

JDRF partners with local clinics and community-based organizations to train CHWs—trusted members of the community—on diabetes technology fundamentals. These CHWs then conduct in-home workshops, one-on-one coaching, and group classes that explain how to set up a CGM, interpret alarms, and integrate insulin pump data into daily decision-making. The program has been particularly successful in Latino and African American communities, where language barriers and cultural mistrust of the medical system often prevent engagement.

Digital Literacy for Diabetes

Many low-income individuals lack the digital literacy skills needed to navigate smartphone apps that accompany modern devices. JDRF’s “Tech for T1D” series offers free webinars, printed guides, and video tutorials in Spanish, English, and simplified Chinese. These resources cover everything from pairing a CGM to a phone to troubleshooting connectivity issues. The program also provides low-cost SIM cards and data plans for those without reliable internet, ensuring that digital access doesn’t become a new form of inequality.

Educational initiatives have shown powerful results. At a clinic in rural Mississippi, after a year of JDRF-supported CHW-led training, CGM use among the clinic’s T1D patients rose from 12% to 45%, and the average A1c dropped by 0.9 percentage points.

Partnerships and Advocacy for Systemic Change

JDRF understands that lasting change requires shifting the policies and systems that perpetuate inequity. The organization works on multiple advocacy fronts:

Medicaid and Medicare Coverage Expansion

JDRF has been a leading voice in urging state Medicaid programs to cover CGMs and insulin pumps without prior authorization or step therapy requirements. The organization’s advocacy efforts have contributed to 38 states now covering CGMs for all people with T1D on Medicaid, up from just 12 in 2020. JDRF also pushes for Medicare to cover newer AID systems and to waive cost-sharing for low-income beneficiaries.

State-Level Legislation

JDRF helps draft and push for state laws that mandate diabetes technology coverage in insurance plans, cap out-of-pocket costs for diabetes supplies, and protect patients from “non-medical switching” where insurers force a device change. In 2024, JDRF-backed legislation in California, New York, and Illinois resulted in annual caps of $100 on CGM supplies for low-income enrollees.

Alliances with Manufacturers and Providers

JDRF sits on advisory boards for major diabetes technology companies, advocating for the creation of lower-cost device tiers, longer-lasting sensors, and prescription-free access to certain products. The organization also works with large health systems like Kaiser Permanente and the Indian Health Service to pilot programs that automatically refer low-income T1D patients for technology assistance upon diagnosis.

A notable example is the JDRF-IBM Watson Health collaboration, which developed an AI-powered algorithm to identify T1D patients in underserved areas who would benefit most from a technology intervention, thereby directing resources to those with the highest need.

Measuring Impact: What the Data Show

JDRF’s initiatives are not just well-meaning—they are producing quantifiable improvements. The organization tracks key metrics through its Health Equity Dashboard, which pulls data from partner clinics, insurance claims, and patient surveys.

  • Device Adoption Rates: Among JDRF program participants, CGM adoption increased by an average of 34% within the first year, compared to a 9% increase in a matched control group not receiving assistance.
  • Health Outcomes: Participants saw a 22% reduction in emergency department visits for hypoglycemia or DKA over 18 months. Time-in-range improved by an average of 23 percentage points.
  • Patient Satisfaction: Over 85% of grant recipients reported that JDRF’s support was “essential” or “very important” to their ability to use advanced technology consistently.

These outcomes demonstrate that targeted financial, educational, and advocacy efforts can close the technology gap. However, JDRF acknowledges that the work is far from complete.

Future Goals: Scaling Sustainable Solutions

JDRF has outlined ambitious targets for the next five years. The organization aims to:

  • Double the number of low-income T1D patients using any CGM or insulin pump by 2030, focusing particularly on rural areas and communities of color.
  • Expand its assistance programs internationally to low- and middle-income countries, where access to diabetes technology is even more scarce. Pilot programs in Kenya and India have already shown promise.
  • Advocate for a federal mandate requiring all insurance plans to cover AID systems for people with T1D, with a sliding-scale cost-sharing mechanism based on income.
  • Invest in long-term research on the health economic impact of technology equity, using data to convince payers and policymakers that upfront device costs are offset by reduced complications and hospitalizations.

The organization is also exploring partnerships with telemedicine providers to offer remote device training and digital diabetes management, eliminating the need for frequent in-person specialist visits—a significant barrier for low-income families without transportation or paid time off.

A Vision of Health Equity

JDRF’s multifaceted approach recognizes that solving the access problem requires more than just lowering prices. It demands a systemic effort that combines direct financial aid, education, advocacy, and policy change. The initial results are promising, but the ultimate goal is a world where every person with type 1 diabetes—regardless of income—can choose the technology that best fits their lifestyle and receive the support needed to use it effectively.

For those who wish to learn more or get involved, JDRF offers resources on its official website and encourages individuals to reach out to their local chapter. Health equity in diabetes is not a niche concern—it is central to the organization’s mission to accelerate life-changing breakthroughs. By ensuring that advanced technologies reach the communities that need them most, JDRF is not just saving lives; it is rewriting the narrative of what is possible for low-income individuals with T1D.